search
Back to results

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock (ECMOxy)

Primary Purpose

Cardiogenic Shock, Extracorporeal Membrane Oxygenation

Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Oxygen gas
Sponsored by
Centre Hospitalier Universitaire de Besancon
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiogenic Shock focused on measuring Cardiogenic shock, Extracorporeal Membrane Oxygenation, Hyperoxia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient supported by veino-arterial ECMO for cardiogenic shock for less than 6 hours
  • Affiliation to social protection

Exclusion Criteria:

  • Age < 18 ans
  • Pregnancy
  • Opposition of the patient or his relatives
  • Cannulation during cardiopulmonary resuscitation
  • Cardiopulmonary resuscitation duration > 10 minutes before ECMO implantation
  • Patient moribound on the day of randomization
  • Chronic hemodialysis
  • Chronic intestinal disease

Sites / Locations

  • CHU de BesançonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Extracorporeal normoxemia

Extracorporeal hyperoxemia

Arm Description

After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%. The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg. PO2 postoxygenator is monitored at least twice a day by the nurse. If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after. Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg. Intervention will be applied for 7 days after randomization.

After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%. The objective is to maintain PO2 postoxygenator higher than 300 mmHg. PO2 postoxygenator is monitored at least twice a day by the nurse. If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed. Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg. Intervention will be applied for 7 days after randomization.

Outcomes

Primary Outcome Measures

Enterocyte damage
Plasma Intestinal Fatty Acid Biding Protein (I-FABP) concentration

Secondary Outcome Measures

Feasibility of the oxygenation protocol
Percentage of time in the oxygenation target
Security of the oxygenation protocol
Number of right radial PaO2 below 80 mmHg
Organ failure
Death or severe stroke (NIHSS > 11) or mesenteric ischemia
Organ failure
Non cardiac component of the Sequential Organ Failure Assessment (SOFA) score
Organ failure
Plasma lactate concentration
Enterocyte damage
Plasma Intestinal Fatty Acid Biding Protein (I-FABP) concentration
Enterocyte function
Difference between plasma citrulline concentrations at day 0 and day 2
Liver failure
Plasma Aspartate aminotransferase (ASAT) concentration
Liver failure
Prothrombine time
Renal failure
Plasma creatinine concentration
Renal failure
Need for renal replacement therapy
Systemic inflammation
Plasma CRP, TNF alpha, IL6 and IL8 concentrations
Anti-oxydant stock
Plasma vitamin C, vitamin E, and Glutathion concentrations

Full Information

First Posted
July 30, 2021
Last Updated
September 28, 2023
Sponsor
Centre Hospitalier Universitaire de Besancon
search

1. Study Identification

Unique Protocol Identification Number
NCT04990349
Brief Title
Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock
Acronym
ECMOxy
Official Title
Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation : Impact on Organ Dysfunction in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 9, 2022 (Actual)
Primary Completion Date
February 9, 2024 (Anticipated)
Study Completion Date
July 9, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Besancon

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Because of dual oxygenation and oxygenator performance (PO2 postoxygenator up to 500 mmHg), hyperoxemia (PaO2 > 150 mmHg) is frequent in veino-arterial ECMO, especially in the lower part of the body, which is mainly oxygenated by ECMO. By enhancing oxygen free radicals' production, hyperoxemia might favor gut, kidney and liver dysfunction. We hypothesize that targeting an extracorporeal normoxemia (i.e. PO2 postoxygenator between 100 and 150 mmHg) will decrease gut, kidney and liver dysfunctions, compared to a liberal extracorporeal oxygenation.
Detailed Description
Randomization: Patients will be randomized in the 6 hours following ECMO start in the normoxemia or in the hyperoxemia group. Randomization will be stratified on center, and medical or postcardiotomy indication for ECMO. Description of experimental arm (Normoxemia group): After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%. The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg. PO2 postoxygenator is monitored at least twice a day by the nurse. If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after. Ventilator's settings at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg. Intervention will be applied for 7 days after randomization. Description of the control arm (Hyperoxemia group): After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%. The objective is to maintain PO2 postoxygenator higher than 300 mmHg. PO2 postoxygenator is monitored at least twice a day by the nurse. If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed. Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg. Intervention will be applied for 7 days after randomization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Keywords
Cardiogenic shock, Extracorporeal Membrane Oxygenation, Hyperoxia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial with two arms
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Extracorporeal normoxemia
Arm Type
Experimental
Arm Description
After randomization, extracorporeal normoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 60%. The objective is to maintain oxygen partial pressure measured on the arterial cannula (PO2 postoxygenator) between 100 and 150 mmHg. PO2 postoxygenator is monitored at least twice a day by the nurse. If PO2 postoxygenator is less than 100 mmHg or more than 150 mmHg, FmO2 is modified by 10% and PO2 postoxygenator is monitored 10 minutes after. Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg. Intervention will be applied for 7 days after randomization.
Arm Title
Extracorporeal hyperoxemia
Arm Type
Active Comparator
Arm Description
After randomization, extracorporeal hyperoxemia is targeted by setting the ECMO membrane oxygen fraction (FmO2) at 100%. The objective is to maintain PO2 postoxygenator higher than 300 mmHg. PO2 postoxygenator is monitored at least twice a day by the nurse. If PO2 postoxygenator is less than 300 mmHg, membrane change should be discussed. Ventilator's setting at let to the clinician's discretion. However, PaO2 on right radial artery will be monitored to ensure that is more that 80 mmHg. Intervention will be applied for 7 days after randomization.
Intervention Type
Drug
Intervention Name(s)
Oxygen gas
Intervention Description
Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
Primary Outcome Measure Information:
Title
Enterocyte damage
Description
Plasma Intestinal Fatty Acid Biding Protein (I-FABP) concentration
Time Frame
At day 2
Secondary Outcome Measure Information:
Title
Feasibility of the oxygenation protocol
Description
Percentage of time in the oxygenation target
Time Frame
From day 0 to day 6
Title
Security of the oxygenation protocol
Description
Number of right radial PaO2 below 80 mmHg
Time Frame
From day 0 to day 6
Title
Organ failure
Description
Death or severe stroke (NIHSS > 11) or mesenteric ischemia
Time Frame
From day 0 to day 30
Title
Organ failure
Description
Non cardiac component of the Sequential Organ Failure Assessment (SOFA) score
Time Frame
At day 0, day 2 and day 6
Title
Organ failure
Description
Plasma lactate concentration
Time Frame
At day 0, day 2 and day 6
Title
Enterocyte damage
Description
Plasma Intestinal Fatty Acid Biding Protein (I-FABP) concentration
Time Frame
At day 0, and day 1
Title
Enterocyte function
Description
Difference between plasma citrulline concentrations at day 0 and day 2
Time Frame
At day 0 and day 2
Title
Liver failure
Description
Plasma Aspartate aminotransferase (ASAT) concentration
Time Frame
At day 0, day 2 and day 6
Title
Liver failure
Description
Prothrombine time
Time Frame
At day 0, day 2 and day 6
Title
Renal failure
Description
Plasma creatinine concentration
Time Frame
At day 0, day 2 and day 6
Title
Renal failure
Description
Need for renal replacement therapy
Time Frame
From 0 to day 6
Title
Systemic inflammation
Description
Plasma CRP, TNF alpha, IL6 and IL8 concentrations
Time Frame
At day 0, day 2 and day 6
Title
Anti-oxydant stock
Description
Plasma vitamin C, vitamin E, and Glutathion concentrations
Time Frame
At day 0, day 2 and day 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient supported by veino-arterial ECMO for cardiogenic shock for less than 6 hours Affiliation to social protection Exclusion Criteria: Age < 18 years old Pregnancy Opposition of the patient or his relatives Cannulation during cardiopulmonary resuscitation Cardiopulmonary resuscitation duration > 10 minutes before ECMO implantation Patient moribound on the day of randomization Chronic hemodialysis Chronic intestinal disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hadrien Winiszewski, MD
Phone
03 81 66 81 27
Email
hwiniszewski@chu-besancon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Gilles Capellier, MD, PhD
Phone
03 81 66 81 27
Email
gilles.capellier@univ-fcomte.fr
Facility Information:
Facility Name
CHU de Besançon
City
Besancon
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hadrien WINISZEWSKI

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Time Frame
2023
Citations:
PubMed Identifier
28787294
Citation
Munshi L, Kiss A, Cypel M, Keshavjee S, Ferguson ND, Fan E. Oxygen Thresholds and Mortality During Extracorporeal Life Support in Adult Patients. Crit Care Med. 2017 Dec;45(12):1997-2005. doi: 10.1097/CCM.0000000000002643.
Results Reference
result
PubMed Identifier
23322670
Citation
Hayes RA, Shekar K, Fraser JF. Is hyperoxaemia helping or hurting patients during extracorporeal membrane oxygenation? Review of a complex problem. Perfusion. 2013 May;28(3):184-93. doi: 10.1177/0267659112473172. Epub 2013 Jan 15.
Results Reference
result
PubMed Identifier
28506763
Citation
Chou HC, Chen CM. Neonatal hyperoxia disrupts the intestinal barrier and impairs intestinal function in rats. Exp Mol Pathol. 2017 Jun;102(3):415-421. doi: 10.1016/j.yexmp.2017.05.006. Epub 2017 May 12.
Results Reference
result
PubMed Identifier
30966908
Citation
Falk L, Sallisalmi M, Lindholm JA, Lindfors M, Frenckner B, Broome M, Broman LM. Differential hypoxemia during venoarterial extracorporeal membrane oxygenation. Perfusion. 2019 Apr;34(1_suppl):22-29. doi: 10.1177/0267659119830513.
Results Reference
result

Learn more about this trial

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

We'll reach out to this number within 24 hrs